NRX-100 clears first-cycle FDA review with no drug deficiencies; approvability via Real World Evidence is the unresolved bet

NRx Pharmaceuticals is a clinical-stage company developing a preservative-free IV ketamine for suicidal depression that is not yet approved, though it has advanced through initial FDA review with no identified drug-related deficiencies.

NRX-100, a preservative-free IV ketamine for suicidal depression, cleared FDA first-cycle review with no drug-related deficiencies, and the sole remaining item is a manufacturer's vial attestation already submitted. Approvability hinges on whether FDA accepts Real World Evidence from 65,000 patients as the primary efficacy basis, an unconventional regulatory path without precedent for this indication. Dilutive financings totaling over $40 million in 2026 and a pending breach-of-contract lawsuit from Kadima add execution and legal risk ahead of the planned 2027 decision.